Ocugen, Inc.

Ocugen's Q3 2026 10-Q discloses substantial doubt about its ability to continue as a going concern within one year, despite $84.3 million in cash and short-term investments. The company incurred a net loss of $47.7 million for the nine months ended September 30, 2026, with an accumulated deficit of $455.7 million and negative operating cash flow of $49.7 million.

The going-concern doubt persists even after a $130.0 million convertible notes offering in May 2026 that generated $112.5 million net proceeds, partly used to repay and terminate the Avenue Capital loan. The notes carry a 6.75% coupon, a ~$2.68 conversion price (versus a $1.03 stock price at quarter-end), and a $17.1 million bifurcated derivative liability that drove $14.7 million of non-cash fair value gains.

A key overhang is the failed September 2026 stockholder vote on increasing authorized shares needed for the Reserved Share Effective Date on the convertible notes; the meeting has been postponed to December 22, 2026. Until approved, notes remain current liabilities and conversions settle in cash, capped at 67.6 million shares.

On the pipeline, OCU400 completed Phase 3 enrollment (N=140) with topline data expected Q1 2027, OCU410ST's Phase 2/3 enrollment finished with data expected Q2 2027, and OCU400 received provisional approval in The Bahamas. Management may need additional capital, partnerships, or strategic alternatives to bridge to these catalysts.